ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Promotion
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > KIR2DL2

KIR2DL2

概要

Name:Killer cell immunoglobulin-like receptor 2DL2
Target Synonym:CD158b1 Antigen,CD158b,P58.2,Receptors, KIR2DL2,CD158k,Cl-43,p58 NK receptor CL-43,CD158B1,Natural killer-associated transcript 6,NKAT6,Killer cell immunoglobulin-like receptor 2DL2,KIR2DL2,Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 2,Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 2,P58 Natural Killer Cell Receptor Clone CL-43,CD158 Antigen-Like Family Member B1,MHC Class I NK Cell Receptor,NKAT-6
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
KI2-H5255 Human Human KIR2DL2 / CD158b1 / NKAT-6 Protein, Fc Tag
KI2-H5255-structure
KI2-H5255-sds
ACRO Quality

生物活性データの一部

KI2-H5255-SPR
KIR2DL2 SPR

Biotinylated Biotinylated Human HLA-C*07:02:01 & B2M & RYR ,His,Avitag™&Tag Free (Cat. No. HLR-H52W2) immobilized on SA Chip can bind Human KIR2DL2, Fc Tag (Cat. No. KI2-H5255) with an affinity constant of 1.01 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol
KI2-H5255-ELISA
KIR2DL2 ELISA

Immobilized Human KIR2DL2, Fc Tag (Cat. No. KI2-H5255) at 1 μg/mL (100 μL/well) can bind Lirilummab with a linear range of 0.2-8 ng/mL (QC tested).

Protocol

Synonym Name

CD158b1

Background

Killer cell immunoglobulin-like receptor 2DL2(KIR2DL2), which belongs to the immunoglobulin superfamily, is an inhibitory receptor of NK cells. KIR2DL2 and KIR2DL3, regulate the activation of natural killer cells (NK) by interacting with the human leukocyte antigen-C1 (HLA-C1) group of molecules. KIR2DL2, KIR2DL3 and HLA-C1 are highly polymorphic, with this variation being associated with differences in the onset and progression of some human diseases.

Clinical and Translational Updates

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Lirilumab IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015 Phase 2 Clinical Novo Nordisk A/S Bone Marrow Neoplasms; Squamous Cell Carcinoma of Head and Neck; Smoldering Multiple Myeloma; Neoplasms; Multiple Myeloma; Urinary Bladder Neoplasms; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap